Sionna Therapeutics (NASDAQ:SION) Director Sells $1,796,558.65 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Bruce Booth sold 55,985 shares of the company’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $32.09, for a total transaction of $1,796,558.65. Following the transaction, the director owned 701,985 shares of the company’s stock, valued at $22,526,698.65. This represents a 7.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Bruce Booth also recently made the following trade(s):

• On Tuesday, October 21st, Bruce Booth sold 88,878 shares of Sionna Therapeutics stock. The shares were sold at an average price of $34.22, for a total transaction of $3,041,405.16.
• On Thursday, October 16th, Bruce Booth sold 169,260 shares of Sionna Therapeutics stock. The shares were sold at an average price of $32.35, for a total transaction of $5,475,561.00.
• On Friday, October 17th, Bruce Booth sold 61,124 shares of Sionna Therapeutics stock. The shares were sold at an average price of $32.37, for a total transaction of $1,978,583.88.
• On Wednesday, October 15th, Bruce Booth sold 115,856 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.61, for a total transaction of $3,546,352.16.
• On Tuesday, October 14th, Bruce Booth sold 606 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total transaction of $18,149.70.
• On Monday, October 13th, Bruce Booth sold 58,232 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.38, for a total transaction of $1,769,088.16.
• On Friday, October 10th, Bruce Booth sold 20,238 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.98, for a total transaction of $606,735.24.
• On Monday, October 6th, Bruce Booth sold 11,800 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total transaction of $353,410.00.
• On Friday, October 3rd, Bruce Booth sold 37,746 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.00, for a total transaction of $1,132,380.00.
• On Wednesday, October 1st, Bruce Booth sold 200 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total transaction of $5,990.00.

Sionna Therapeutics Price Performance

Shares of NASDAQ SION opened at $38.90 on Thursday. Sionna Therapeutics, Inc. has a twelve month low of $7.26 and a twelve month high of $43.19. The firm has a 50-day moving average of $26.55 and a two-hundred day moving average of $19.06.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.27.

Hedge Funds Weigh In On Sionna Therapeutics

Hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets acquired a new position in shares of Sionna Therapeutics in the 2nd quarter valued at $31,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Sionna Therapeutics in the 2nd quarter valued at $45,000. Virtus Investment Advisers LLC acquired a new position in shares of Sionna Therapeutics in the 2nd quarter valued at $96,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Sionna Therapeutics in the 2nd quarter valued at $117,000. Finally, New York State Common Retirement Fund acquired a new position in shares of Sionna Therapeutics in the 2nd quarter valued at $118,000.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on SION shares. Weiss Ratings reissued a “sell (d)” rating on shares of Sionna Therapeutics in a report on Wednesday, October 8th. Wall Street Zen raised shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Royal Bank Of Canada initiated coverage on shares of Sionna Therapeutics in a research note on Wednesday, September 3rd. They set a “sector perform” rating and a $22.00 price objective for the company. Jones Trading initiated coverage on shares of Sionna Therapeutics in a research note on Monday, September 8th. They set a “buy” rating and a $46.00 price objective for the company. Finally, Raymond James Financial initiated coverage on shares of Sionna Therapeutics in a research note on Tuesday, September 2nd. They set a “strong-buy” rating and a $45.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Sionna Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $38.00.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.